This can help prevent future occurrences and may be important for legal or medical follow-ups
For the broader basics on this drug class, see our GLP-1 starter guide
Clinical trials showed an average of ~6% weight reduction after 12 weeks, then ~10% after 20 weeks
Quality statement 8: Monitoring after discharge from the bariatric surgery service (QS212)
The study received funding from Wellcome, Medical Research Council, European Union Horizon 2020 Programme, the National Institutes of Health (grants U01-DK105535, U01-DK085545 and UM-1DK126185), the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim and Diabetes Australia.
BioLongevity Labs supplies 5-Amino-1MQ for research use only